London’s Punto Health Raises €2.3M To Expand AI Dementia Care Platform

The round was co-led by Shilling VC and Plus Partners, with participation from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest.

“Dementia is never just one person’s disease. It affects entire families, and carers often carry an enormous invisible burden. We are building technology that turns a reactive, crisis-driven system into proactive, personalised support that fits into people’s real lives,” said Anna Muñoz-Farré, CEO and co-founder of Punto Health.

Earlier this year, in June, Punto Health won the second edition of the NN Social Innovation Startup Award at The Next Web Conference in Amsterdam, receiving €100k and a year-long mentorship from NN Group and Rubio Impact Ventures. Before that, in May 2024, the company closed a €645k investment round, which builds on a €718.5k ($840k) pre-Seed investment.

Founded in 2023 in London by engineers Anna Muñoz-Farré and Jack Eckersley, Punto Health is a digital health company developing AI-powered tools for early detection and personalized support in dementia and cognitive decline.

Read Also - Trendtracker Secures $7M To Expand AI-Driven Strategic Intelligence Platform

The company has developed an operating system for dementia care: a multilingual digital platform that connects patients, carers, and clinicians through three core products. PuntoTest is an AI-powered, speech-based tool for assessing cognitive impairment in adults.

PuntoCare is a companion app offering care plans, cognitive exercises, nutrition guidance, symptom tracking, physical activity support, and overall wellness resources for patients, carers, and active seniors. The clinician-facing PuntoClinic dashboard aggregates patient-reported outcomes and biomarker data, enabling personalized, data-driven decision-making while supporting both clinical practice and research.

Punto Health’s platform is co-designed and clinically validated in partnership with Ace Alzheimer Centre Barcelona. Together, they are developing a speech-based digital biomarker capable of detecting changes in cognitive status providing clinicians with a detailed view of disease progression across multiple cognitive domains.

In Spain, PuntoTest has already been tested in a rapid cognitive screening programme in collaboration with Ace Alzheimer Centre and Nutricia, covering ten pharmacies in Barcelona and involving over 1,500 participants aged 50 and above.

The platform is also being piloted at North London NHS FT, NHS Oxleas FT, Hospital del Mar in Barcelona, and Hospital General de Granollers, among others.

Currently, Punto Health supports more than 200 users aged 60 to 90, who have completed over 30,000 activities, with more than two-thirds reporting improved confidence in managing daily routines.

“As a technical founder, I have the chance to build a team that looks more like the real world, and to show young women that they belong in AI and health tech. But most of all, I want families to feel they have a trusted companion at every step, not just a diagnosis and a pile of leaflets,” said Muñoz-Farré.

The company is a finalist in the VIII Edición de los Premios Discapnet by Fundación ONCE. It has also been selected for prestigious programs including AD Moonshot by Startup Health, the Alzheimer’s Drug Discovery Foundation, and the AI-First Google Accelerator 2025.

About Punto Health

Punto Health connects patients, families, and healthcare providers via an AI-powered platform that delivers continuous, personalized support. From early cognitive impairment to advanced dementia, the platform acts as a trusted companion helping users navigate care, monitor progress and access tailored guidance for improved well-being and informed decision-making.